Miyazaki Akira, Sakai Masakazu, Sakamoto Yuichiro, Horiuchi Seikoh
Department of Biochemistry, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan.
Curr Opin Investig Drugs. 2003 Sep;4(9):1095-9.
Acyl-coenzyme A:cholesterol acyltransferase (ACAT; Sterol O-acyltransferase/SOAT) is an intracellular enzyme that catalyzes the formation of cholesteryl esters from cholesterol and fatty acyl-coenzyme A. ACAT inhibitors reduce plasma cholesterol levels by suppressing absorption of dietary cholesterol and by suppressing the assembly and secretion of apolipoprotein B-containing lipoproteins such as very low density lipoprotein in liver and chylomicron in intestine. Moreover, ACAT inhibitors prevent the conversion of macrophages into foam cells in the arterial walls. Thus, ACAT inhibitors are under investigation for controlling hypercholesterolemia and the development of atherosclerosis. Some potent ACAT inhibitors have been tested for their efficacy and safety in humans.
酰基辅酶A:胆固醇酰基转移酶(ACAT;甾醇O-酰基转移酶/SOAT)是一种细胞内酶,可催化胆固醇和脂肪酰基辅酶A形成胆固醇酯。ACAT抑制剂通过抑制膳食胆固醇的吸收以及抑制肝脏中含载脂蛋白B的脂蛋白(如极低密度脂蛋白)和肠道中乳糜微粒的组装与分泌来降低血浆胆固醇水平。此外,ACAT抑制剂可防止动脉壁中的巨噬细胞转化为泡沫细胞。因此,正在研究ACAT抑制剂用于控制高胆固醇血症和动脉粥样硬化的发展。一些强效ACAT抑制剂已在人体中进行了疗效和安全性测试。